Card image cap
Transdermal patch, Adlarity, approved for AD-linked dementia

The US FDA has approved once-weekly use of Adlarity, a transdermal patch of donepezil, in 5 mg/day or 10 mg/day formulations to treat patients with mild, moderate or severe dementia associated with Alzheimer’s Disease (AD). The patch, which can be placed by a patient or caregiver on a patient’s back, thigh or buttocks, delivers a consistent dose of donepezil through the skin, resulting in a low likelihood of adverse gastrointestinal side effects associated with oral donepezil. Patients may be switched from 5 mg/day or 10 mg/day oral donepezil directly to Adlarity by their prescriber. Adlarity is a brand of Corium Inc, a US-based biopharmaceutical company.

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.


Supported by Koye Pharmaceuticals

Submit a Comment